Nature Cell on track for clinical trials of Alzheimer’s disease therapy
[THE INVESTOR] Korea’s biotech company Nature Cell said on Dec. 4 that the first patient was successfully administered an injection dosage of its stem cell drug for Alzheimer’s disease as part of phase 2 clinical trials in the US.
The company has been administrating the brain disorder therapy candidate AstroStem, which was jointly developed by Nature Cell and its affiliate Biostar Stem Cell Research Institute, intravenously multiple times to six US patients since July. It said its first patient has received 10 injections which contains 200 million stem cells each.
Biostar Stem Cell Research Institute CEO Ra Jeong-chan
“We will add safety data for the initial four patients and plan to apply for the same protocol to the Korea Ministry of Food and Drug Safety within this year in order to complete the clinical trials by next year in the US and Korea at the same time,” Biostar Stem Cell Research Institute CEO Ra Jeong-chan said.
None of the patients complained of serious side effects or negative reaction during the clinical trials, proving the drug’s safety in the short term, according to the company.
The clinical trials are being conducted at Syrentis Clinical Research and ATP Clinical Research in California, and a hospital in Hawaii.
The phase 1 and 2 clinical trials for the Alzheimer’s disease therapy were approved by the US Food and Drug Administration in November 2016.
By Park Han-na (firstname.lastname@example.org)